Baxter International ended 2024 on a positive note, overcoming challenges posed by Hurricane Helene and delivering better-than-expected Q4 results. The success of the Novum IQ infusion pump ...

Following the completion of a massive restructuring plan, the medical equipment giant projects 4% to 5% sales growth this year.

So I'll say, we're very happy with the launch of Novum IQ and where we are. The teams are doing a great job driving this new platform. If you recall, Baxter placed a pretty big bet to internally ...

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the fourth quarter and full year ended Dec. 31, 2024, and provided its ...

This positive performance was partly attributed to the successful launch of the Novum IQ infusion pump, which contributed to a 50% growth in the infusion business. Looking ahead, Baxter has ...

Baxter International Inc (BAX) reports robust earnings growth and outlines strategic priorities for 2025 despite facing operational challenges.

Baxter calculates forward-looking non-GAAP financial measures based on forecasts that omit certain amounts that would be included in GAAP financial measures. For instance, forward-looking ...